Brucellosis

IMAGE:  The research, published in The Lancet Infectious Diseases is the fruit of joint project between investigators from around the world to conduct the largest individual patient data meta-analysis to... view more  Credit: © 2020 IMSUT, The University of Tokyo CC-BY The research, published in The Lancet Infectious Diseases is the fruit of joint project between investigators from around the world to conduct the largest individual patient data meta-analysis to date under The WorldWide Antimalarial Resistance NetworkWWARNumbrella. The study found that artemether-lumefantrine (AL) (*1) and other artemisinin-based combination therapies (ACTs) (*2) were significantly more effective than quinine, the current recommended treatment. Authors urgently call for further investigation into dose optimisation for pregnant women to ensure the highest possible treatment success. A joint research group consisting of WWARN, A joint research group consisting of WWARN,The Nuffield Department of Me

A study partially conducted at the University has identified a new vaccine target for malaria with a novel mechanism underlying its ability to confer immunity. Malaria produces a detrimental effect on children in areas most gravely afflicted by the disease — but this vaccine candidate, which has not yet been tested in humans, may provide some hope for the future.  The paper was published in Nature , a renowned research journal, on April 22, just prior to World Malaria Day on April 25. A team of scientists — co-lead by Patrick Duffy and Michal Fried of the National Institutes of Health and Jonathan Kurtis ’89 PhD’95 MD’96 — discovered a system of conferring immunity through a novel mechanism of activating cell death. Kurtis is a chair and professor of pathology and laboratory medicine at the University, as well as the director of laboratories for the Lifespan Center for International Health Research .  The project is the culmination of roughly two decades of work that began shor

Image Source: freerangestock.com - Free Commercial Images Readers seem to be very interested in IDEXX ( IDXX ) but authors haven't covered the name with the frequency demanded by demand. A decision was then made to update my previous article on the company. But please note that certain aspects of the business haven't changed much since the first article was published back in August 2019: for instance, IDEXX's competitive advantages, core markets, reporting segments, and so on are (as expected) unaltered. Still, as new readers might benefit from the analysis, these 'evergreen' aspects will be covered once again in the following article. Please skip the following introduction if you have read my previous articles. Introduction It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. " Whether we're talking about socks or stocks, I like buying quality merchandise when it is marked down ." - Warren B

CHICAGO (WBBM NEWSRADIO) --  Statewide, the number of people who tested positive for chlamydia in the first three months of this year was about half the number of positives from 2019. Illinois health officials said fewer people are being tested this year.   Here in Chicago, Chad Hendry, director of sexual and reproductive health at Howard Brown Health, is seeing the same thing: fewer people being tested for sexually transmitted infections. “Over the last two months for gonorrhea and chlamydia, the numbers have dramatically decreased. Probably between 44 to 48 percent as compared to the same time last year," Hendry said.  But the percentage of positives is a different story: Hendry said more of those who are being tested for STIs are testing positive -- a higher percentage of positives than last year at this time. Probably, he said, because of COVID-19 fears or whatever, they don’t come in to be tested unless they have symptoms. Hendry said for a couple of weeks, Howard Brow

Montana Department of Livestock HELENA — The Montana Department of Livestock is encouraging the public to submit comments to remove brucellosis from the select agent — or bioterror — list. Diseases on the select agent list have severe restrictions on research because they could pose a threat to human, animal or plant health. Including brucellosis on the list has prevented research that could have led to new vaccines, diagnostics and other methods of disease control, Montana State Veterinarian Dr. Marty Zaluski said. “Without better tools, especially vaccines, brucellosis will continue to spread in Greater Yellowstone Area wildlife, expose more livestock, and increase management costs.”   “While the intent of including brucellosis on the select agent list was to limit the availability of the bacteria, it’s having the opposite effect,” Zaluski added. “The disease is becoming more broadly distributed on the landscape and we have few tools to stop it.”  Both the USDA Animal and Plan